Infectious diseases in post-trial detention and comparisons with pre-trial detention: A study in Geneva, Switzerland

Baggio, Stéphanie; Pala, Komal Rachna Chacowry; Rieder, Jean-Pierre; Wolff, Hans; Gétaz, Laurent

doi:10.1016/j.jiph.2019.11.001

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 More than 10.35 million people are incarcerated in jails and prisons throughout the world. 3 The prevalence of HCV infection among prisoners varies around the world: 2.8% in Geneva post-trial prisons, 4 3.4% among Iranian prisoners, 5 11.5% in Swedish prisoners in Stockholm County, 6 and 23.1% in Taiwan. 7 In the United States, the rate varies by location: 10.1% at two prison facilities in New York State, 8 and 34.3% at California State correctional facilities.…”

Section: Introductionmentioning

confidence: 99%

The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons

Richter

Goldstein²,

Cohen

et al. 2022

Science Progress

View full text Add to dashboard Cite

Background Direct-acting antiviral (DAA) regimens and telemedicine services are both options for treating hepatitis C virus (HCV) within the prison setting. We aimed to compare factors associated with HCV treatment success over the past decade in Israeli prisons, specifically the influence of DAAs and telemedicine. Methods We retrospectively reviewed the medical records of inmates with HCV infection in Israeli prisons from 2010 through 2020. Demographic, clinical, and laboratory data were recorded, including treatment regimens and success rates. Results A total of 273 inmates were treated; mean age 45 ± 9.36 years; 98.2% males; 63.9% with a history of drug abuse. Advanced fibrosis was documented in 42.9%. The most common genotypes were 1 (46%) followed by 3 (40.7%). Interferon-based regimens were given to 68 inmates between 2010 and 2017. DAA agents were introduced in 2016, with pan-genotype regimens being exclusively used since 2019. Telemedicine services were used in 140 patients (51.3%), starting in February 2019. The sustained viral response (SVR) rate with interferon-based therapy was 78.8% and 98.8% with DAA treatment, giving an overall SVR of 93.2%. This difference between regimens proved to be the only statistically significant predictor of treatment success. The number of prisoners being treated with DAAs increased exponentially after telemedicine was introduced. Comparable SVR rates were achieved with either in-person or telemedicine consultation. Conclusion Screening of this high-risk population and using telemedicine for treatment may be an effective strategy for the elimination of HCV from the prison population.

show abstract